National Center for Advancing Translational Sciences

Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain Cancers

Retrieved on: 
Thursday, November 9, 2023
Colon, Medication, Weight gain, Research, Argyreia nervosa, CB2, National Center for Advancing Translational Sciences, Senior, Quality of life, Trinity College, Life expectancy, Trinity College Dublin, Cancer, Pain, Patient, Associate, Atrophy, Appetite, Pharmaceutical industry, Medical device, Vitro

The research article, titled “ Cancer-Cachexia-Induced Human Skeletal Muscle Myotube Degeneration is Prevented via Cannabinoid Receptor 2 Agonism in Vitro ,” highlights the promising protective properties of the Company’s clinical asset, ART27.13, in helping prevent muscle degeneration caused by cancer.

Key Points: 
  • The research article, titled “ Cancer-Cachexia-Induced Human Skeletal Muscle Myotube Degeneration is Prevented via Cannabinoid Receptor 2 Agonism in Vitro ,” highlights the promising protective properties of the Company’s clinical asset, ART27.13, in helping prevent muscle degeneration caused by cancer.
  • Senior author Dr. Richard K. Porter, Associate Professor at Trinity College Dublin, Ireland, stated, “This groundbreaking research demonstrated ART27.13’s ability to protect against muscle degeneration associated with colon and lung cancers.
  • The purpose of this new research was to establish whether ART27.13 may additionally impact muscle degradation, a common debilitating effect of cancer and its treatment.
  • Not only did the research show that ART27.13 protects against muscle wasting in the in vitro model, but also shows that the activity was mediated by the CB2 receptor.

ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights

Retrieved on: 
Tuesday, November 7, 2023
SLRN, Research, American College, MDA, Quality of life, Inflammation, Doctor of Philosophy, Hidradenitis suppurativa, Graves' ophthalmopathy, GxP, Disease, DRS, LOS, LEI, I&I, Secukinumab, Shep, Abscess, Shepherd (name), Axial spondyloarthritis, Amgen, Webcast, TED, Safety, Patient, D, Week, FRCP, MD, MRCP, Development, Growth, Clinical trial, Internal, Suicidal ideation, INC, Enthesitis, Psoriatic arthritis, FDA, CMC, Poster, National Center for Advancing Translational Sciences, Senior, Psoriasis, IL-17A, Cryptocurrency, Pharmaceutical industry, Medical device, Management

LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reported financial results for the third quarter ended September 30, 2023 and highlighted additional corporate updates and milestones.

Key Points: 
  • (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reported financial results for the third quarter ended September 30, 2023 and highlighted additional corporate updates and milestones.
  • For the quarter ended September 30, 2023, these expenses include a stock-based compensation expense of $11.7 million.
  • Net Loss: Net loss totaled $83.9 million for the third quarter of 2023, or $0.87 per share, compared to $14.4 million or $8.17 per share for the third quarter of 2022.
  • ET to review its third quarter 2023 financial results.

Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates

Retrieved on: 
Monday, November 6, 2023
Ovarian cancer, Research, PARP, AACR, Acute myeloid leukemia, Therapy, USC, G&A, Conference, WEE1, Maintenance, R, Clinical Ovarian Cancer & Other Gynecologic Malignancies, National Center for Advancing Translational Sciences, Senior, Development, Uterine serous carcinoma, Biology, Partnership, Cancer, GSK, Medication, ORR, Platinum, Culture, NDA, Genentech, Safety, Amyloidosis, American Association for Cancer Research, Patient, Administration, SAN, State Administrative Expenses, Pharmaceutical industry

“Azenosertib continues to show very encouraging monotherapy anti-tumor activity, safety and tolerability in both ovarian cancer and uterine serous carcinoma.

Key Points: 
  • “Azenosertib continues to show very encouraging monotherapy anti-tumor activity, safety and tolerability in both ovarian cancer and uterine serous carcinoma.
  • Zentalis is the only company known to have both a WEE1 inhibitor, azenosertib, and a BCL-2 inhibitor, ZN-d5, in clinical development.
  • Research and Development Expenses: Research and development (R&D) expenses for the quarter ended September 30, 2023 were $46.8 million, compared to $42.2 million for the quarter ended September 30, 2022.
  • General and Administrative Expenses: General and administrative (G&A) expenses for the quarter ended September 30, 2023 were $16.0 million, compared to $12.0 million during the quarter ended September 30, 2022.

Virpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Review

Retrieved on: 
Tuesday, October 31, 2023
Other Health, Research, General Health, Pharmaceutical, Medical Devices, Infectious Diseases, Science, Surgery, Biotechnology, FDA, Other Science, Health, Post-traumatic stress disorder, Rat, Analgesic, Nanotechnology, National Center for Advancing Translational Sciences, IND, Central nervous system disease, Food, NCATS, Chronic pain, Hematology, Mortality, Morphine, US Food Sovereignty Alliance, CNS, Nanoparticle, Administration, Human, Traffic barrier, Transitive dependency, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Completeness, DRF, Thermoregulation, Animal, Brain, NIH, CFA, Pain management, Drug tolerance, Dog, Pain, MET, Hypersensitivity, Bangladesh Technical Education Board, Coagulation, Central nervous system, Pharmaceutical industry

Envelta utilizes a novel and patented intranasal drug delivery system, Molecular Envelope Technology (MET) to bypass the blood-brain barrier.

Key Points: 
  • Envelta utilizes a novel and patented intranasal drug delivery system, Molecular Envelope Technology (MET) to bypass the blood-brain barrier.
  • The MET was developed by Nanomerics, Ltd. , a UK-based nanotechnology research and development company that has licensed its MET-LENK to Virpax.
  • The nose-to-brain MET platform protects molecules from biodegrading and enhances the bioavailability of product candidates on its transport to the brain.
  • “We are grateful to the FDA for the thorough and clear direction that was provided to us in our pre-IND meeting.

Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update

Retrieved on: 
Monday, October 23, 2023
Desmosine, Șaeș, National Center for Advancing Translational Sciences, Atalanta, Aes, NCATS, Biomarker, UAB, BMD, European Medicines Agency, Liver, Infection, Critical care, OI, Division, Osteogenesis imperfecta, EMA, CT, University, NIH, Safety, University of Alabama, QTC, Patient, Neutropenia, Bangladesh Technical Education Board, COPD, Pharmaceutical industry, Medical imaging

LONDON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on recent program developments and third quarter 2023 financial information.

Key Points: 
  • LONDON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on recent program developments and third quarter 2023 financial information.
  • The Phase 3 portion of the study is currently enrolling approximately 195 patients at 50 sites across 12 countries.
  • There was no difference in the proportion of patients with treatment-related Adverse Events (AEs) between the alvelestat and placebo arms.
  • The data from the ATALANTa study are expected to further support the ongoing partnering process for the alvelestat Phase 3 program.

Applied BioMath, LLC Announces Participation at AAPS 2023 PharmSci 360

Retrieved on: 
Thursday, October 19, 2023
Drug development, Science, Patient, Harvard John A. Paulson School of Engineering and Applied Sciences, Mathematical and theoretical biology, CSO, Bi-specific T-cell engager, Simulation, Doctor of Philosophy, AAPS, R, National Center for Advancing Translational Sciences, Messenger, UGT1A1, Biomarker, Translation, Crigler–Najjar syndrome, Pharmaceutical industry, Medical imaging, Management, Medical device

CONCORD, Mass., Oct. 19, 2023 /PRNewswire/ -- Applied BioMath ( www.appliedbiomath.com ), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced their participation at AAPS 2023 PharmSci 360 occurring October 22-25, 2023 in Orlando, FL.

Key Points: 
  • CONCORD, Mass., Oct. 19, 2023 /PRNewswire/ -- Applied BioMath ( www.appliedbiomath.com ), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced their participation at AAPS 2023 PharmSci 360 occurring October 22-25, 2023 in Orlando, FL.
  • Applied BioMath will participate in multiple presentations during the conference.
  • Joshua Apgar, PhD, Co-founder and CSO at Applied BioMath will give a Speaker Spotlight presentation entitled, "Evolving Clinical Pharmacology and Translational PK/PD Approaches for New Modalities" on Tuesday, October 24th from 9:30-10:30am.
  • To learn more about Applied BioMath, visit www.appliedbiomath.com .

Taysha Gene Therapies Announces Two Poster Presentations on TSHA-102 in Rett Syndrome at Upcoming European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

Retrieved on: 
Tuesday, October 10, 2023
Congress, Drug, Central nervous system, Cell, Risk, Gene, MECP2, AAV, Poster, Bachelor of Medicine, Bachelor of Surgery, CET, ESGCT, European Society of Gene and Cell Therapy, CNS, Rett syndrome, National Center for Advancing Translational Sciences, Pharmaceutical industry

DALLAS, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced that it will present data on its TSHA-102 program in evaluation for Rett syndrome during two poster presentations at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress, taking place in Brussels, Belgium from October 24-27, 2023.

Key Points: 
  • DALLAS, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced that it will present data on its TSHA-102 program in evaluation for Rett syndrome during two poster presentations at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress, taking place in Brussels, Belgium from October 24-27, 2023.
  • TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy that utilizes a novel miRNA-Responsive Auto-Regulatory Element (miRARE) technology designed to mediate levels of MECP2 in the CNS on a cell-by-cell basis without risk of overexpression.
  • The Company will present new preclinical in vitro data supporting the miRARE technology, as well as initial clinical data from the first adult patient dosed with TSHA-102 in the REVEAL Phase 1/2 adult trial.
  • Poster presentation details are as follows:
    Presenters: Emdadul Haque, Ph.D., Director, Translational Sciences, and Fred Porter, Ph.D., Chief of Staff and Technical Operations Officer, Taysha Gene Therapies
    Poster Session Date/Time: Wednesday, October 25 at 17:00-18:15 CET and Thursday, October 26 at 20:30-21:30 CET
    Presenter: Benit Maru, MBChB, Ph.D., Chief Medical Officer and Head of Clinical Development, Taysha Gene Therapies
    Poster Session Date/Time: Wednesday, October 25 at 18:15-19:30 CET and Thursday, October 26 at 19:30-20:30 CET

Owens Corning Reports Progress on Shingle Recycling Initiatives

Retrieved on: 
Monday, October 16, 2023
Environment, Recycling, Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, Multimedia, OC, NCAT, NYSE, Industrial waste, National Center for Advancing Translational Sciences, RAS, Shingles, Carbon, Owens Corning, Tar, Fine chemical, Road

Owens Corning (NYSE: OC) continues to advance toward its aspiration to create a circular shingle economy and divert waste from landfills.

Key Points: 
  • Owens Corning (NYSE: OC) continues to advance toward its aspiration to create a circular shingle economy and divert waste from landfills.
  • The company announced today that it has made progress on two key shingle recycling workstreams important for reaching its goal of recycling two million tons of shingles per year in the U.S. by 2030.
  • (Photo: Business Wire)
    In late 2022, Owens Corning and its partners launched an asphalt shingle recycling pilot developed to deconstruct residential and industrial waste shingles and extract their component materials.
  • “The progress being made at the pilot is a very promising step toward the future of shingle recycling,” said Gunner Smith, Owens Corning Roofing President.

Rett Syndrome Research Trust's Genetic Medicines Summit Sets the Stage for Accelerated Therapeutic Development

Retrieved on: 
Wednesday, October 11, 2023
Office of Rare Diseases Research, Food, Doctor of Philosophy, Biomarker, National Center for Advancing Translational Sciences, RSRT, Critical Path Institute, RNA, Harvard University, MD, DNA, Therapy, Summit, Center for Biologics Evaluation and Research, MPH, Roger Hawkins (drummer), IND, MacNamara, JD, Biotechnology, P.C, Rare, United States Department of the Army, MECP2, EEG, FDA, Broad Institute, Hyman, MIT, RNA editing, Clinical trial, Wuhan Institute of Biological Products, Bangladesh Technical Education Board, Regulation of tobacco by the U.S. Food and Drug Administration, COA, Rett syndrome, Pharmaceutical industry, Medical imaging, Rett, Research

TRUMBULL, Conn., Oct. 11, 2023 /PRNewswire-PRWeb/ -- The Rett Syndrome Research Trust (RSRT) is delighted to announce the successful conclusion of the inaugural Rett Syndrome Genetic Medicines Summit, held September 13 – 15 in Boston, Massachusetts. This landmark event gathered distinguished scientists, clinicians, regulatory experts, and over 40 leading biopharma companies. The goal of the Summit was to foster dialogue among scientific, clinical, industry, and regulatory stakeholders to facilitate collaboration, identify best practices, and refine expectations to expedite pre-clinical and clinical development programs focused on genetic medicines for children and adults with Rett syndrome.

Key Points: 
  • The Rett Syndrome Research Trust (RSRT) is delighted to announce the successful conclusion of the inaugural Rett Syndrome Genetic Medicines Summit, held September 13 – 15 in Boston, Massachusetts.
  • TRUMBULL, Conn., Oct. 11, 2023 /PRNewswire-PRWeb/ -- The Rett Syndrome Research Trust (RSRT) is delighted to announce the successful conclusion of the inaugural Rett Syndrome Genetic Medicines Summit, held September 13 – 15 in Boston, Massachusetts.
  • RSRT's Rett Syndrome Genetic Medicines Summit underscores the organization's unwavering commitment to curing Rett syndrome.
  • RSRT remains steadfast in its mission to accelerate the development of genetic therapies and ultimately find a cure for Rett syndrome.

ASHA Joins Nonpartisan Coalition for Trust in Health & Science

Retrieved on: 
Wednesday, September 27, 2023
Distrust, American Speech–Language–Hearing Association, Public, Coalition, American Association for Respiratory Care, Trust, Doctor of Philosophy, Health policy, Bangladesh Technical Education Board, ASHA, Public health, National Center for Advancing Translational Sciences, Health, Compendium, Nursing, Science

ROCKVILLE, Md., Sept. 27, 2023 /PRNewswire-PRWeb/ -- The American Speech-Language-Hearing Association (ASHA) announced today that it has joined the Coalition for Trust in Health & Science, a non-partisan and non-profit undertaking for countering the escalation of mistrust and distrust in health care, public health, and science.

Key Points: 
  • Nonprofit Works to Counter the Escalation of Mistrust and Distrust in Health Care, Public Health, and Science
    ROCKVILLE, Md., Sept. 27, 2023 /PRNewswire-PRWeb/ -- The American Speech-Language-Hearing Association (ASHA) announced today that it has joined the Coalition for Trust in Health & Science, a non-partisan and non-profit undertaking for countering the escalation of mistrust and distrust in health care, public health, and science.
  • "ASHA has long advocated, practiced, and provided evidence-based decision-making, practice, and guidance," ASHA 2023 President Robert M. Augustine, PhD, CCC-SLP, said.
  • "The Coalition for Trust in Health & Science is excited to welcome ASHA, and the expertise of its members to our increasingly important initiative," said Reed Tuckson MD, a cofounder of the Coalition.
  • Members include more than eighty organizations that represent health care and health systems; public health and health policy; basic and applied science; pharmaceutical and device manufacturers; health care communicators; and philanthropy and foundations.